相关实验视频

Updated: Sep 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

评价中子捕获疗法作为不可切除的胃肠道 stromal 瘤的潜在治疗方法

Seita Hagihara¹, Jun Arima², Yasuhiko Ueda¹

¹Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

|June 25, 2025

概括

中子捕获疗法 (BNCT) 显示出治疗胃肠道 stromal 瘤 (GIST) 的前景,即使是那些对 imatinib 耐药的瘤. BNCT有效地抑制了瘤生长,并通过DNA损伤诱导癌细胞死亡.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
分子生物学分子生物学

背景情况:

胃肠道 stromal 瘤 (GIST) 通常会对标准的伊马替尼治疗产生抗性.
新的治疗策略对于不可切除和复发性GIST至关重要.
中子捕获疗法 (BNCT) 提供了一种针对癌细胞根除的有针对性的方法.

研究的目的:

研究BNCT作为GIST的潜在治疗方法的疗效.
在对伊马替尼布敏感和对伊马替尼布耐药的GIST模型中评估BNCT.

主要方法:

使用GIST-T1和GIST-T1/IM-R细胞系进行体外和体内研究.
在GIST细胞中评估烯氨酸 (BPA) 的吸收.
在小鼠模型中通过生存分数分析和瘤生长抑制来评估BNCT的疗效.

主要成果:

基氨酸被有效地纳入了两个GIST细胞系.
与单独的中子辐射相比,BNCT显著降低了GIST细胞存活率.
在体内,BNCT显著抑制了瘤生长,并诱导了亡和DNA损伤标志物.

结论:

通过诱导亡和DNA损伤,BNCT有效地抑制了GIST瘤的生长.
BNCT为GIST提供了一个有前途的替代疗法,包括对伊马替尼布耐药的病例.

关键词:

在 BNCT 上,你会发现.BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA BPA 这就是GIST GIST.伊马替尼布 (Imatinib) 的使用情况在LAT-1中使用LAT-1.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...